Description

Tirzepatide Sodium Overview

Tirzepatide Sodium is a synthetic peptide developed for laboratory research into dual receptor pathways involving glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Its distinct sequence and structure have made it a key subject of interest in metabolic and biochemical studies focused on peptide–receptor interactions and metabolic regulation mechanisms.

• Amino Acid Sequence: YE-Aib-GTFSDYSI-Aib-LDKIAQ (C20 fatty acid) AFVQWLIAGGPSSGAPPPS

• Note: Aib is a non-coded (non-proteinogenic) amino acid – H₂H-C(CH₃)₂-COOH

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

• Molecular Weight: 4813.527 g/mol

• PubChem CID: 156588324

• CAS Number: 2023788-19-2

• Incretin Pathway Research: Studied for its dual agonist activity on GIP and GLP-1 receptors, offering insights into glucose and lipid metabolism in laboratory models.

• Receptor Binding Studies: Its structural features make it a strong candidate for investigating receptor binding and pathway activation in non-clinical research.

This compound is intended strictly for research purposes only. It is not approved for human or veterinary use. Proper laboratory safety protocols must be followed when handling Tirzepatide Sodium.

All information provided is for scientific and educational purposes only. This material is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption.

• Supplied exclusively for scientific research use.

• Provided as a lyophilized (freeze-dried) powder in a sealed, sterile vial.

• Label quantity reflects the total content per vial.

• Additional laboratory materials are required, including bacteriostatic water for reconstitution, syringes, needles, and alcohol prep pads for vial sanitization.

• Vial appearance, cap, seal, and label may vary from product images.